Pulike Biological Engineering, Inc.

SHSE:603566 Stock Report

Market Cap: CN¥4.3b

Pulike Biological Engineering Past Earnings Performance

Past criteria checks 2/6

Pulike Biological Engineering has been growing earnings at an average annual rate of 5.8%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 14.8% per year. Pulike Biological Engineering's return on equity is 5%, and it has net margins of 11.7%.

Key information

5.8%

Earnings growth rate

4.7%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate14.8%
Return on equity5.0%
Net Margin11.7%
Next Earnings Update30 Aug 2024

Recent past performance updates

Recent updates

Pulike Biological Engineering, Inc. (SHSE:603566) Looks Just Right With A 34% Price Jump

May 21
Pulike Biological Engineering, Inc. (SHSE:603566) Looks Just Right With A 34% Price Jump

Need To Know: The Consensus Just Cut Its Pulike Biological Engineering, Inc. (SHSE:603566) Estimates For 2024

Apr 28
Need To Know: The Consensus Just Cut Its Pulike Biological Engineering, Inc. (SHSE:603566) Estimates For 2024

Why Investors Shouldn't Be Surprised By Pulike Biological Engineering, Inc.'s (SHSE:603566) Low P/E

Mar 21
Why Investors Shouldn't Be Surprised By Pulike Biological Engineering, Inc.'s (SHSE:603566) Low P/E

Pulike Biological Engineering (SHSE:603566) Seems To Use Debt Quite Sensibly

Feb 28
Pulike Biological Engineering (SHSE:603566) Seems To Use Debt Quite Sensibly

Revenue & Expenses Breakdown

How Pulike Biological Engineering makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:603566 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 241,181138485104
31 Dec 231,253175478101
30 Sep 231,329225477102
31 Mar 231,29219448894
31 Dec 221,23016848993
30 Sep 221,10514245675
30 Jun 221,03216142270
31 Mar 221,03519540481
31 Dec 211,09924440086
30 Sep 211,10229836989
30 Jun 211,086271361113
31 Mar 211,044255339118
31 Dec 20929228302115
30 Sep 20840175278118
30 Jun 2076516424587
31 Mar 2070915423176
31 Dec 1966310923591
30 Sep 1964811223092
30 Jun 1964212423092
31 Mar 1961211122794
31 Dec 1860813622073
30 Sep 1858014120467
30 Jun 1855712919188
31 Mar 1854111920373
31 Dec 1753011421461
30 Sep 1753712422935
30 Jun 175921602600
31 Mar 175991782510
31 Dec 165831882450
30 Sep 165431812200
30 Jun 165051612100
31 Mar 164651391980
31 Dec 154781421940
30 Sep 154671521900
30 Jun 154861581870
31 Mar 154991611950
31 Dec 144761401930
31 Dec 134721631710

Quality Earnings: 603566 has high quality earnings.

Growing Profit Margin: 603566's current net profit margins (11.7%) are lower than last year (15%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 603566's earnings have grown by 5.8% per year over the past 5 years.

Accelerating Growth: 603566's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 603566 had negative earnings growth (-29.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).


Return on Equity

High ROE: 603566's Return on Equity (5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.